Ehave's Bioinformatics Platform Technology to
Be Used to Evaluate Aequus' Products in Multiple Neurological
Disorders
VANCOUVER, March 5, 2018 /CNW/ - Aequus Pharmaceuticals Inc.
(TSX-V: AQS) (OTCQB: AQSZF) ("Aequus" or the
"Company"), a specialty pharmaceutical company with a focus
on developing, advancing and promoting differentiated products, and
Ehave, Inc. (OTCQB: EHVVF) ("Ehave"), a healthcare
bioinformatics company whose platform efficiently captures,
integrates, and delivers high-quality clinical data and treatment
tools, have entered into a collaboration agreement whereby Aequus
will incorporate Ehave's bioinformatics platform to enhance and
streamline data management processes for Aequus-sponsored clinical
trials studying specific Cannabinoid-rich formulations for treating
a number of neurological disorders. The Companies had been working
together under a previously announced Letter of Intent established
in August 2017.
"Our thinking regarding conducting clinical trials of various
cannabinoid containing formulations has advanced substantially
since we signed the original Letter of Intent with Ehave. We have a
number of different trials in late-stage planning and see multiple
opportunities for us to leverage our traditional pharmaceutical
expertise in designing and implementing clinical programs, but we
also see growing opportunities for us to leverage our existing
relationships with Canadian clinicians and take advantage of our
existing pharmaceutical sales infrastructure to better serve
clinicians and Insurers as it relates to medical cannabis. We and
Ehave are in a unique position to generate meaningful product
safety and efficacy data in a variety of trial settings in a very
efficient and cost-effective way," says Doug Janzen, Chairman and CEO of Aequus. "In our
most recent comprehensive physician survey regarding factors that
prevent them from recommending medical cannabis products, Canadian
clinicians identified the lack of robust clinical data in a
real-world setting for such products as a significant limiting
factor."
"Our robust bioinformatics platform allows us to provide
customized, next-generation clinical solutions that empower
pharmaceutical developers such as Aequus to be successful," said
Prateek Dwivedi, CEO of Ehave. "We
are particularly committed to partnering with companies seeking to
evaluate medical cannabis products, recognizing the specific need
within this emerging industry for 'pharmaceutical-grade' patient
and clinical data informatics to help unlock the value of these new
therapies for clinicians, patients, and payors. Aequus shares this
view based on its strong background, unique capabilities and
commercial experience in traditional pharmaceutical development,
making them an ideal partner for Ehave. We look forward to helping
them advance their clinical programs and potentially improve
outcomes for patients with neurological disorders who may benefit
from Aequus' products."
The terms of the agreement are similar to that of the original
Letter of Intent. Aequus will pay Ehave a per-patient fee for
trials conducted using Ehave's platform and Aequus will receive
patient assessment, diagnostic and therapeutic outcomes and
side-effect profile content from formal and informal studies
conducted using the Ehave platform, subject to standard patient
consent and clinical research ethics approvals. Aequus will own all
clinical results and data generated from trials using the Ehave
platform.
About Aequus Pharmaceuticals
Aequus Pharmaceuticals Inc. (TSX-V:AQS, OTCQB: AQSZF) is
a growing specialty pharmaceutical company focused on developing
and commercializing high quality, differentiated products. Aequus'
development stage pipeline includes several products in neurology
and psychiatry with a goal of addressing the need for improved
medication adherence through enhanced delivery systems. With a
focus in neurology and other specialty areas, our most recent
addition to the development pipeline was a long-acting form of
medical cannabis, where there is a high need for a consistent,
predictable and pharmaceutical-grade delivery of products for
patients. Aequus intends to commercialize its internal programs in
Canada alongside its current
portfolio of marketed established medicines and will look to form
strategic partnerships that would maximize the reach of its product
candidates worldwide. Aequus plans to build on its Canadian
commercial platform through the launch of additional products that
are either created internally or brought in through an acquisition
or license; remaining focused on highly specialized therapeutic
areas. For further information, please
visit www.aequuspharma.ca.
About Ehave, Inc.
Ehave, Inc. (OTCQB: EHVVF) is empowering the mental healthcare
community with a next generation of data-rich tools designed to
improve patient management, diagnosis and treatment. With Ehave
Connect, Ehave's mental health informatics platform, clinicians can
make objective, data-driven decisions while keeping patients
informed and engaged throughout their mental healthcare journey.
Ehave Connect offers a powerful set of core features that integrate
with a growing selection of tools and applications developed by
Ehave and its leading partners, including Multi-Health Systems
("MHS"), a leading publisher of psychological assessments. Ehave is
initially focused on improving the standard of care in attention
deficit hyperactivity disorder ("ADHD"), through its collaboration
with the Hospital for Sick Children ("SickKids"). Ehave Connect is
also being utilized to advance the validation and optimization of
medical cannabis, through its collaboration with leading medical
cannabis licensed producers. For more information,
visit www.ehave.com.
Aequus Pharmaceuticals Inc. Forward-Looking
Statements:
This release may contain forward-looking statements or
forward-looking information under applicable Canadian securities
legislation that may not be based on historical fact, including,
without limitation, statements containing the
words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect", "potential" and
similar expressions. Forward-looking statements are necessarily
based on estimates and assumptions made by us in light of our
experience and perception of historical trends, current conditions
and expected future developments, as well as the factors we believe
are appropriate. Forward-looking statements in this release include
but are not limited to statements relating to: identifying barriers
to current use and potential product offerings in specific
therapeutic areas, and using results
from Ehave's bioinformatics platform to
monitor and assess patient outcomes. Such statements reflect our
current views with respect to future events and are subject to
risks and uncertainties and are necessarily based upon a number of
estimates and assumptions that, while considered reasonable by
Aequus, are inherently subject to significant business, economic,
competitive, political and social uncertainties and contingencies.
Many factors could cause our actual results, performance or
achievements to be materially different from any future results,
performance, or achievements that may be expressed or implied by
such forward-looking statements. In making the forward-looking
statements included in this release, the Company has made various
material assumptions, including, but not limited to: obtaining
positive results of clinical trials, obtaining regulatory
approvals, general business and economic conditions, the Company's
ability to successfully out-license or sell its current products
and in-license and develop new products, the assumption that the
Company's current good relationships with its manufacturer and
other third parties will be maintained, the availability of
financing on reasonable terms, the Company's ability to attract and
retain skilled staff, market competition, the products and
technology offered by the Company's competitors and the Company's
ability to protect patents and proprietary rights. In evaluating
forward-looking statements, current and prospective shareholders
should specifically consider various factors set out under the
heading "Risk Factors" in the Company's
Annual Information Form dated April 29,
2016, a copy of which is available on
Aequus' profile on the SEDAR website at
www.sedar.com, and as otherwise disclosed from time to
time on Aequus' SEDAR profile. Should one or more of
these risks or uncertainties, or a risk that is not currently known
to us materialize, or should assumptions underlying those
forward-looking statements prove incorrect, actual results may vary
materially from those described herein. These forward-looking
statements are made as of the date of this release and we do not
intend, and do not assume any obligation, to update these
forward-looking statements, except as required by applicable
securities laws. Investors are cautioned that forward-looking
statements are not guarantees of future performance and are
inherently uncertain. Accordingly, investors are cautioned not to
put undue reliance on forward-looking statements.
Ehave, Inc. Forward-Looking Statement
Disclaimer
This press release contains "forward-looking
statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Such statements may be
preceded by the
words "intends," "may," "will," "plans," "expects," "anticipates,""projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or
similar words. Forward-looking statements are based on certain
assumptions and are subject to various known and unknown risks and
uncertainties, many of which are beyond the Company's control, and
cannot be predicted or quantified and consequently, actual results
may differ materially from those expressed or implied by such
forward-looking statements: (i) the initiation, timing, progress
and results of the Company's research, manufacturing and other
development efforts; (ii) the Company's ability to advance its
products to successfully complete development and
commercialization; (iii) the manufacturing, development,
commercialization, and market acceptance of the Company's products;
(iv) the lack of sufficient funding to finance the product
development and business operations; (v) competitive companies and
technologies within the Company's industry and introduction of
competing products; (vi) the Company's ability to establish and
maintain corporate collaborations; (vii) loss of key
management personnel; (viii) the scope of protection the Company is
able to establish and maintain for intellectual property rights
covering its products and its ability to operate its business
without infringing the intellectual property rights of others; (ix)
potential failure to comply with applicable health information
privacy and security laws and other state and federal privacy and
security laws; and * the difficulty of predicting actions of the
USA FDA and its regulations. All
forward-looking statements included in this press release are made
only as of the date of this press release. The Company assumes no
obligation to update any written or oral forward-looking statement
unless required by law. More detailed information about the Company
and the risk factors that may affect the realization of
forward-looking statements is contained under the heading "Risk
Factors" in Ehave, Inc.'s Registration Statement on Form F-1 filed
with the Securities and Exchange Commission (SEC) on September 24, 2015, as amended, which is
available on the SEC's
website, http://www.sec.gov.
SOURCE Aequus Pharmaceuticals Inc.
